Navigation Links
Atherosclerosis Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com
Date:7/29/2015

The report “Atherosclerosis - Pipeline Review, H1 2015” provides comprehensive information on the therapeutic development for Atherosclerosis. Atherosclerosis is a slow, progressive disease that may start in childhood. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report on Atherosclerosis Pipeline with 78 market data tables and 15 figures, spread across 276 pages is available at http://www.rnrmarketresearch.com/atherosclerosis-pipeline-review-h1-2015-market-report.html .

Companies discussed in this Atherosclerosis - Pipeline Review, H1 2015 report include Ache Laboratorios Farmaceuticos, advanceCor GmbH, AFFiRiS AG, Arisaph Pharmaceuticals, Inc., Artery Therapeutics, Inc., AstraZeneca Plc, Athera Biotechnologies AB, AtheroNova Inc., AuraSense Therapeutics, LLC, Bayer AG, Bridge Bioresearch Plc, Campus Technologies Freiburg G, Cardax Pharmaceuticals, Inc., ChemoCentryx, Inc., CohBar Inc., DoNatur GmbH, Dr. Reddy's Laboratories Limited, Dybly AG, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GenKyoTex S.A., Gilead Sciences, Inc., Isis Pharmaceuticals, Inc., Jenrin Discovery, Inc., Johnson & Johnson, KineMed, Inc., Kowa Company, Ltd., Lead Discovery Center GmbH, MedImmune, LLC, Merck & Co., Inc., MI.TO. Technology S.r.L., Novartis AG, Omeros Corporation, OPKO Health, Inc., Otsuka Holdings Co., Ltd., Provid Pharmaceuticals, Inc., Resverlogix Corp., The Medicines Company, Therapix Biosciences Ltd, Vascular Biogenics Ltd., Vericel Corporation, Vitae Pharmaceuticals, Inc.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Drug Profiles mentioned in this report are 6860766, AEM-28, AG-01, AHRO-001, AHRO-002, AHRO-003, aliskiren fumarate, AM-0010, anacetrapib, Annexin A-5, Antisense Oligonucleotide to Inhibit Cide B for Hyperlipidemia and Atherosclerosis, ARI-1778, Artpep-2, ATH-03, ATH-04, ATH-05, ATH-06, AZ-876, BAY-606583, BSN-272, CCX-771, CCX-872, CDX-085, Cell Therapy for Atherosclerosis, CM-7, COR-2, CSN-501, CVX-210H, D-4F, DIAS-2, DRL-17822, Drug for Atherosclerosis, Drug to Agonize TLR-4 for Metabolic Disorders, Immunology and Cardiovascular Disease, Drugs for Cardiovascular Diseases, Drugs to Activate TLR3 for Atherosclerosis, Drugs to Antagonize NMDA Receptor for Atherosclerosis, DYB-186, EP-80317, evacetrapibFX-5A, Gene Therapy for Arteriosclerosis and Endothelial Dysfunction, Gene Therapy to Activate Interleukin 10 for Atherosclerosis, Gene Therapy to Target miR-145 for Atherosclerosis, GKT-136901, GKT-137831, GKT-901, GYY-4137, Humanin, INV-88, ISIS-APOARx, ixmyelocel-T, JD-6000 Series, K-312, K-877, KM-011, KRP-206, LDN-193189, LPC-01, MCS-18, MDCO-216, MEDI-6012, Small Molecule to Target GPR132 for Atherosclerosis, Small Molecules for Atherosclerosis, Small Molecules for Atherosclerosis, SPX-7233801, Stem Cell Therapy for Atherosclerosis, SYN-20110119RU, VB-201, VTP-4.

Order a purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=397254 . (This is a premium report priced at US$2000 for a single user License.)

Partial List of Tables
Number of Products under Development for Atherosclerosis, H1 2015 19
Number of Products under Development for Atherosclerosis - Comparative Analysis, H1 2015 20
Number of Products under Development by Companies, H1 2015 22
Number of Products under Development by Companies, H1 2015 (Contd..1) 23
Number of Products under Development by Companies, H1 2015 (Contd..2) 24
Number of Products under Development by Companies, H1 2015 (Contd..3) 25
Number of Products under Investigation by Universities/Institutes, H1 2015 27
Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 28
Comparative Analysis by Late Stage Development, H1 2015 29
Comparative Analysis by Clinical Stage Development, H1 2015 30
Comparative Analysis by Early Stage Development, H1 2015 31
Products under Development by Companies, H1 2015 32
Products under Development by Companies, H1 2015 (Contd..1) 33
Products under Development by Companies, H1 2015 (Contd..2) 34
Products under Development by Companies, H1 2015 (Contd..3) 35
Products under Development by Companies, H1 2015 (Contd..4) 36
Products under Investigation by Universities/Institutes, H1 2015 37
Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 38
Atherosclerosis - Pipeline by Ache Laboratorios Farmaceuticos S/A, H1 2015 39
Atherosclerosis - Pipeline by advanceCor GmbH, H1 2015 40
Atherosclerosis - Pipeline by AFFiRiS AG, H1 2015 41
Atherosclerosis - Pipeline by Arisaph Pharmaceuticals, Inc., H1 2015 42
Atherosclerosis - Pipeline by Artery Therapeutics, Inc., H1 2015 43
Atherosclerosis - Pipeline by AstraZeneca Plc, H1 2015 44
Atherosclerosis - Pipeline by Athera Biotechnologies AB, H1 2015 45
Atherosclerosis - Pipeline by AtheroNova Inc., H1 2015 46
Atherosclerosis - Pipeline by AuraSense Therapeutics, LLC, H1 2015 47
Atherosclerosis - Pipeline by Bayer AG, H1 2015 48
Atherosclerosis - Pipeline by Bridge Bioresearch Plc, H1 2015 49
Atherosclerosis - Pipeline by Campus Technologies Freiburg GmbH, H1 2015 50

Explore more reports on Pharmaceuticals at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals .

About Us:
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.

Read the full story at http://www.prweb.com/releases/atherosclerosis-pipeline/review-h1-2015-market/prweb12875944.htm.


'/>"/>
Source: PRWeb
Copyright©2015 Vocus, Inc.
All rights reserved

Related medicine news :

1. Linking vascular inflammation to obesity and atherosclerosis
2. Pain Management Therapeutics Market to 2019 - Impact of Patent Expiries Offset by Demand for Neuropathic and Rheumatoid Pain Medications and Strong Pipeline
3. Orphan Drugs in Oncology Drug Pipeline Update 2013
4. Immunovaccine, Inc. - Product Pipeline Review - 2013
5. Future of the Healthcare Industry Depends on Building the Hispanic Pipeline; City of Hope’s Dr. Susan Kane Discusses this Urgent Need on HealthyHispanicLiving.com
6. Bacterial Skin and Skin Structure Infections Market: SSSI Pipeline Review, H2 2013 at ReportsnReports.com
7. AGA showcases its commitment to improving the pipeline of minority researchers
8. ProtonPACS Announces Pipeline Partnership with the National Rural Health Association.
9. Pipeline Analysis of Hospital Acquired Pneumonia Drugs Market Reveals Six Potential Late Stage Candidates and Ten Late Stage Candidates: Transparency Market Research
10. Tinnitus Therapeutic Company and Drugs Profiles Pipeline Review H2 2014 in a New Report Available at RnRMarketResearch.com
11. Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Apple ... care services, staged a mock evacuation of the facility as part of a disaster ... Fire Department, Echo Hose EMS and Shelton City Emergency Manager, as well as the ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Global Healthcare Management’s ... Alexandria Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s ... The fun run is geared towards children of all ages; it is a ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the ... danger possible to save lost souls in the Philippines. “The Journey: From the Mountains ... a dedicated teacher of the Bible. She has taught all ages and currently teaches ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the largest and ... plans to open a flagship location in Covington, LA at 401 N. U.S. Highway ... store next to Office Depot in the Holiday Square shopping center. Its location allows ...
(Date:10/12/2017)... ... 2017 , ... Asante, a nationally recognized health system in ... existing home health joint venture through an agreement, effective October 1, 2017, to ... home health company with Asante, delivering clinically integrated care, for the past eight ...
Breaking Medicine News(10 mins):
(Date:10/10/2017)... -- NDS received FDA 510(k) clearance in May 2017 for its highly ... designed for endoscopy environments. An innovative secondary monitor solution, ZeroWire ... support the improvement of patient outcomes, procedural efficiency, and the lowering ... ... ...
(Date:10/4/2017)... 4, 2017  South Korean-based healthcare product Development Company ... "cprCUBE" on Kickstarter. The device will educate the user ... with better efficiency compared to the dated and pricey ... on efficacy of the compression for a more informed ... goal to raise $5,000. ...
(Date:10/2/2017)... 2017  Eli Lilly and Company (NYSE: ... third quarter of 2017 on Tuesday, October 24, 2017. ... day with the investment community and media to further ... call will begin at 9 a.m. Eastern time. Investors, ... webcast of the conference call through a link that ...
Breaking Medicine Technology: